Summary Bis-acetato-ammine-dichloro-cyclohexylamine-platinum (IV) (Fukuoka et al. 1991 : McGuire et al. 1996 . These agents available today are. however, generally administered intravenously. The development of an oral platinum drug has been desired to improve the quality of life of patients receiving cancer chemotherapy in terms of easy administration. Bis-acetato-ammine-dichloro-cvclohexylamineplatinum (IV). JM2 16. is the first oral antineoplastic platinum agent currently under development. In preclinical studies. JM' 16 exhibited in vitro and in vivo anti-tumour efficacy comparable with cisplatin and carboplatin. and an activity against cell lines that were resistant to cisplatin (Kelland et al. 1993) . Several phase H clinical trials of JM216 monotherapy have already been performed in the United States and Europe. and a phase I study has finished in Japan (Groen et al. 1996 : Fujii et al. 1997 : Peereboom et al. 1997 . Further, some combination regimens of JM216 with other anti-tumour agents. such as taxans. can be expected. but no information on the potential dru2 interactions bet-een JM2 16 and other drugs has been reported.
Platinum anti-tumour agents. such as cisplatin and carboplatin. have been widely used in combination chemotherapy for many cancers. especially for ovarian and lung cancers (Fukuoka et al. 1991 : McGuire et al. 1996 . These agents available today are. however, generally administered intravenously. The development of an oral platinum drug has been desired to improve the quality of life of patients receiving cancer chemotherapy in terms of easy administration. Bis-acetato-ammine-dichloro-cvclohexylamineplatinum (IV). JM2 16. is the first oral antineoplastic platinum agent currently under development. In preclinical studies. JM' 16 exhibited in vitro and in vivo anti-tumour efficacy comparable with cisplatin and carboplatin. and an activity against cell lines that were resistant to cisplatin (Kelland et al. 1993) . Several phase H clinical trials of JM216 monotherapy have already been performed in the United States and Europe. and a phase I study has finished in Japan (Groen et al. 1996 : Fujii et al. 1997 : Peereboom et al. 1997 . Further, some combination regimens of JM216 with other anti-tumour agents. such as taxans. can be expected. but no information on the potential dru2 interactions bet-een JM2 16 and other drugs has been reported.
The metabolic pathway of the drug is complicated and has not been well understood (Raynaud et al. 1996) . However, there are some implications that metabolism of JM216 might affect drugmetabolizing enzymes in the liver. First. at least six metabolites were detected in plasma samples from patients who received JM216 (Raynaud et al. 1996) . Four of them were also obtained by in mvitro incubations with fresh human plasma. whereas the remaining two metabolites were detected orly in in vivo studies.
Second. according to the results of organ distribution in mice platinum accumulated to a high level in the liver and the level was retained steadily for several days (McKeage et al. 1994) .
Besides the metabolic pathway of JM216 itself. it is important to evaluate the effects of the drug on the metabolism of other drugs. This study was undertaken to investigate whether JM216 would interact with drugs being metabolized by cytochrome P450 (CYP). (Waxman et al. 1988) . paclitaxel 6a-hydroxylation (CYP2C8) (Cresteil et al. 1994 : Rahman et al. 1994 . 7-ethoxyresorufin O-deethylation (CYPlAl. CYPIA2) (Guengerich et al. 1982) . coumarin 7-hydroxylation (CYP2A6) (Pearce et al. 1992) . aniline p-hydroxylation (CYP2EI) (Ryan et al. 1985 ) and (±)-bufuralol l'-hydroxylation (CYP2D6) (Nakamura et al. 1996 calculated by the peak height of the metabolite using a standard curve generated by the authentic standard. Biotransformation of paclitaxel was determined according to the method reported by Harris et al (1994) with minor modifications. Incubation mixture consisted of 100 mm potassium phosphate buffer (pH 7.4). 50 gM EDTA, 0.4-1 mg of microsomal protein. an NADPH-generating system and JM216 or cisplatin in a final volume of I ml. Each reaction was initiated by adding 10 l of a paclitaxel solution (0.25-2.0 mM) in methanol. After 15-min incubation. the reactions were eliminated by adding 5 ml of acetonitrile containing 0.5 IM baccatin m as an internal standard. Tubes were vortexed and centrifuged, and the resultant supematant was evaporated to dryness. The residue was dissolved in 200 gl of 1:1 acetonitrile-water before HPLC analysis. Under the conditions described above, baccatin ml 6a-hydroxypaclitaxel and pacitaxel were eluted with retention times of 18.2 min, 24.5 min and 26.7 min respectively, which were similar to those reported by Harris et al (1994) . As an authentic reference standard of the metabolite of paclitaxel was not available, we assumed that the metabolite eluted with a retention time of 24.5 min as 6a-hydroxypaclitaxel and expressed the velocity of biotransformation as the peak height ratio of the metabolite to the intemal standard.
MATERIALS AND METHODS
7-Ethoxyresorufin O-deethylation and coumarin 7-hydroxylation were measured by determination of metabolites using a Hitachi F-2000 fluorescence spectrophotometer (Hitachi, Tokyo. Japan: Lake, 1987; Pearce et al, 1992) . Aniline p-hydroxylation was assayed colorimetrically with a Hitachi U-1000 spectrophotometer (Hitachi; Imai et al. 1966 ). The l'-hydroxylated metabolite of (±)-bufuralol was determined by HPLC as reported previously (Nakamura et al, 1996) . Incubation times were 10 min for 7-ethoxyresorufin (with a final concentration of 2 PIM), 15 min for coumarin (50 gM), 15 min for aniline (4 mM) and 30 min for (±)-bufuralol (20 giM) oxidations.
RESULTS
Effects of JM216 on the 6-hydroxylation of testosterone Clear inhibition by JM216 of testosterone 6$-hydroxylation was seen. At the 160 gM concentration of testosterone, an IC-value was estimated to be between 0.3 ILM and 1 JM, suggesting a strong inhibitory effect of JM216 on CYP3A (Figure 1) . Lineweaver-Burk plots showed that the inhibition occurred in a non-competitive manner. and the K value derived from the secondary plots was evaluated to be 1.0 JLM (Figure 2 ). The hydroxylase also seemed to be inhibited by cisplatin, but the inhibition was rather weak. The inhibition was only 15% at 10 Jim concentration of cisplatin (Figure 1 ).
Effects of JM216 on the metabolism of paclitaxel
The hydroxylation of pactitaxel was inhibited with an IC-, value between 1 JiM and 3 gM at a paclitaxel concentration of 10 Jim (Figure 1) . Fonnation of the metabolite, possibly 6a-hydroxypaclitaxel, followed Michaelis-Menten kinetics as demonstrated by linear Lineweaver-Burk plots (Figure 3 ). Apparent Km value was 17 gm, which was consistent with that measured as the formation of 6a-hydroxypaclitaxel in previous reports (Cresteil et al. 1994; Harris et al, 1994) . The inhibition also occurred in a noncompetitive manner with the K, value of 0.9 jim (Figure 3) .
Oter inhibfiton studies
The activities of 7-ethoxyresorufin O-deethylase. coumarin 7-hydroxylase. anili p-hydroxylase and (±)-bufuralol l'-hydroxylase were inhibited by JM216 as well (Figure 1) . The ICfo values were between 3 jim and 10 gM for 7-ethoxyresorufin O-deethylase, between 1 pM and 3 jM for coumarin 7-hydroxylase and aniline p-hydroxylase, and between 0.3 jM and 1 giM for (±)-bufuralol l'-hydroxylase, indicating non-specific inhibitory effects of JM216 on CYP. On the other hand, cisplatin exhibited only scant effects on CYP activities.
DISCUSSION
Several drugs, such as SKF-525A (Buening and Franklin. 1974) . metyrapone (Testa and Jenner. 1981), cimetidine (Winzor et al. 1986 ) and ketoconazole (Pasanen et al, 1988) , have been known to inhibit CYP non-specifically. JM2 16 would be another example of a non-specific inhibitor of CYP with high inhibition potential. Thus, more detailed mechanism(s) responsible for the inhibition should be investigated.
Further, it remains to be examined whether phamicokinetics of drugs being metabolized mainly by CYP would be altered by JM216. As in vitro results do not always translate to the in vivo situation, and as very little or no JM216 is found in the systemic circulation after oral administration in human (Raynaud et al. 1996) , we cannot be sure exactly how much, if any, of the compound actually reaches the liver through the portal vein. The in vitro inhibition of CYP by JM216 found in this study, however, agrees with the results of combination chemotherapy involving etoposide in vivo (Rose. 1997) . When etoposide was given orally to mice in combination with JM216, the maximum tolerated dose was reduced to 25% of that seen with etoposide alone. Although no pharmaokinetic data were reported. it might be possible that JM216 inhibited the metabolism of etoposide. a substrate of CYP3A (Relling et al, 1994) .
This report suggests that careful attention should be paid to interactions of drugs metabolized mainly by CYP, including many antineoplastic agents, when treating cancer patients with JM216. Additionally, if the in vitro/in vivo correlations are demonstrated. we can propose an advantageous use of JM216 as a potential suppresser of drug metabolism in combination cancer chemotherapy. In other words, JM216 can be used to reduce the necessary dose for treatment of combined agents that are detoxified by CYPs, i.e. paclitaxel (CYP2C8. CYP3A4: Cresteil et al. 1994; Harris et al, 1994; Rahman et al, 1994) . docetaxel (CYP3A4; Marre et al, 1996) , etoposide (CYP3A4: Relling et al, 1994) and vinca alkaloids (CYP3A4; Zhou et al, 1993) . With this kind of intervention, the inhibition of cyclosporin or etoposide metabolism by ketoconazole has already been used intentionally to reduce the cost of cyclosporin treatment and to improve the bioavailability of oral etoposide (First et al, 1989; Kobayashi et al. 1996) . Schwartz et al (1995) have successfully used fluconazole to reverse the accelerated trans-retinoic acid clearance in patients with acute promyelocytic leukaemia On the other hand. as cyclophosphamide and ifosfamide are activated by CYP2B and CYP3A respectively (Chang et al. 1993) . combination use of JM2 16 may decrease the anti-tumour effects of these prodrugs.
This in vitro study revealed that JM2 16 inhibited multiple forms of CYP. Therefore, some in vivo studies should be conducted to determine whether or not there is a correlation between in vivo and in vitro results.
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